002524 Guangzheng Eye Hospital Group
- 3.89
- -0.02-0.51%
Guangzheng Eye Hospital Group News
Guangzheng Ophthalmology (002524.SZ): Currently, no visual prevention and control products have been developed and produced
Gelonghui, March 29丨An investor asked Guangzheng Ophthalmology (002524.SZ) on the investor interactive platform. Regarding “whether your company researches and produces myopia prevention and control products,” the company replied that the company has not yet developed and produced vision prevention and control products. The company provides patients with myopia prevention and control diagnosis and treatment services and solutions, and has good cooperative relationships with mainstream myopia prevention and control product suppliers.
Guangzheng Eye Hospital Group Co., Ltd.'s (SZSE:002524) 26% Share Price Surge Not Quite Adding Up
Guangzheng Eye Hospital Group Co., Ltd. (SZSE:002524) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recent
Guangzheng Ophthalmology (002524.SZ): 2023 pre-profit of 8 million yuan to 12 million yuan
Ge Longhui, January 29丨Guangzheng Ophthalmology (002524.SZ) announced the 2023 annual performance forecast. Operating income for the reporting period was 1060 million yuan to 1080 million yuan 767.4446 million yuan, up 38.12% to 40.73% over the same period of the previous year; net profit attributable to shareholders of listed companies was 8 million yuan to 12 million yuan, or -78.1776 million yuan in the same period last year; net profit after deducting non-recurring profit and loss was -4 million yuan to -2 million yuan, compared to -291.681 million yuan for the same period last year; basic per share Earnings of 0.02 yuan to 0.
Guangzheng Eye Hospital Group Co., Ltd.'s (SZSE:002524) Shares May Have Run Too Fast Too Soon
When close to half the companies in the Healthcare industry in China have price-to-sales ratios (or "P/S") below 1.8x, you may consider Guangzheng Eye Hospital Group Co., Ltd. (SZSE:002524) as a stock
Guangzheng Ophthalmology (002524.SZ): Ophthalmology revenue for the third quarter increased 50% year-on-year
Glonghui, Oct. 24, 丨 Guangzheng Ophthalmology (002524.SZ) said on the investor interactive platform that with the restoration of the special external environment and the deepening of the company's brand and service advantages, the company's ophthalmology sector has continued to improve since this year; the third quarter reported a 50% year-on-year increase in ophthalmology revenue; net profit was positive, and 143% year-on-year.
Investors Are Selling off Guangzheng Eye Hospital Group (SZSE:002524), Lack of Profits No Doubt Contribute to Shareholders Three-year Loss
Many investors define successful investing as beating the market average over the long term. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report
[Instant Analysis of BT Financial Report] Guangzheng Ophthalmology 2023 Third Quarter Report: Net Assets Increase, Gross Margin Increase, Net Profit Fall
Announcement time of this financial report: 2023-10-20 19:28:17 Guangzheng Ophthalmology Hospital Group Co., Ltd. (stock code: 002524) is a professional ophthalmology chain medical enterprise, mainly engaged in the investment and management of ophthalmology hospitals. The company has set up ophthalmology hospitals and optometry clinics in central cities such as Shanghai, Chengdu, Chongqing, Zhengzhou, Nanchang, Hohhot, Jinan, Qingdao, Wuxi, and Yiwu to provide professional diagnosis and treatment services covering all types of ophthalmology diseases to patients all over the country. According to the company's financial report for the third quarter of 2023, the company's total assets reached 15 at the end of the reporting period.
Guangzheng Ophthalmology (002524.SZ) released third-quarter results, net profit of 5.263,600 yuan, a year-on-year decrease of 97.31%
Guangzheng Ophthalmology (002524.SZ) released its report for the third quarter of 2023, and the company's revenue was 280 million yuan...
Guangzheng Ophthalmology (002524.SZ): Since this year, revenue from corneal plastic lenses has increased markedly year-on-year
Glonghui, October 16丨Guangzheng Ophthalmology (002524.SZ) said on the investor interactive platform that the company has a corneal plastic lens business and has a good reputation and product service advantages in core markets such as Shanghai. Since this year, revenue from corneal plastic lenses has increased markedly year-on-year. For details of the annual turnover, please refer to the company's subsequent annual report.
Guangzheng Ophthalmology (002524.SZ): Granting 8544,900 restricted shares to 286 incentive recipients
Glonghui, September 19, 丨 Guangzheng Ophthalmology (002524.SZ) announced that the initial grant conditions stipulated in the company's 2023 restricted stock incentive plan have been fulfilled. The board of directors agreed to set the initial grant date as September 19, 2023, and award 85449.46 million restricted shares to 286 eligible incentive recipients at a grant price of RMB 3.30 per share.
Guangzheng Ophthalmology (002524.SZ) plans to introduce a restricted stock incentive plan in 2023 with an initial grant price of 3.30 yuan/share
Guangzheng Ophthalmology (002524.SZ) released the 2023 Restricted Stock Incentive Plan (draft). This incentive plan...
Guangzheng Ophthalmology (002524.SZ): Net profit of 5.172,200 yuan in the first half of the year was reversed year-on-year
Glonghui, August 24, 丨 Guangzheng Ophthalmology (002524.SZ) released its semi-annual report. Operating income was 546 million yuan, up 60.08% year on year, net profit of 5.172,200 yuan, reversing losses from the previous year. After deducting non-net profit of 4,078,500 yuan, losses were reversed year on year, and basic earnings per share were 0.01 yuan.
Guangzheng Ophthalmology (002524.SZ): Complete the repurchase at a cumulative cost of 9.7762 million yuan to buy back 1.5 million shares
GLONGHUI August 11丨Guangzheng Ophthalmology (002524.SZ) announced that as of August 10, 2023, the company's share repurchase plan has been implemented. The actual share repurchase range of the company was from July 20, 2023 to August 10, 2023. A total of 1.5 million shares of the company's shares were purchased through centralized bidding transactions through a dedicated securities repurchase account, accounting for about 0.2911% of the company's total share capital. The maximum transaction price was 6.78 yuan/share, the minimum transaction price was 6.35 yuan/share, and the total transaction amount was 97762.44 million yuan (excluding transaction fees).
Guangzheng Ophthalmology (002524.SZ): Purchased 1.15 million shares at a cumulative cost of 7.414,700 yuan
GLONGHUI, August 1 | Guangzheng Ophthalmology (002524.SZ) announced that as of the close of trading on July 31, 2023, the company implemented the above share repurchase plan through centralized bidding transactions through the repurchase of a dedicated securities account. The total amount paid was 1.15 million shares of the company, accounting for 0.22% of the company's current total share capital. The maximum transaction price was 6.66 yuan/share, the minimum transaction price was 6.35 yuan/share, and the total amount paid was 7.41447 million yuan (excluding transaction fees).
Guangzheng Ophthalmology (002524.SZ): The penetration rate of refractive surgery, OK lens correction or treatment methods is still low, and the market space is broad
GLONGHUI July 31丨Some investors asked Guangzheng Ophthalmology (002524.SZ): What are the opportunities and history of the company's transformation into the healthcare service industry? Reply from Guangzheng Ophthalmology: Before 2018, Guangzheng's main business was the traditional steel structure and natural gas industry. Affected by the external environment and industry cycle, the overall profitability was average. Under these circumstances, the company actively sought transformation, conducted in-depth research on various industries, and after careful analysis and decision making, finally chose to enter the ophthalmology circuit as a business that will continue to be cultivated for decades to come. The market space for eye care services is huge. China is the country with the largest number of eye patients in the world, according to
Guangzheng Ophthalmology (002524.SZ): Initial repurchase of 400,000 shares involving 2,54867 million yuan
On July 20, 2023, GLONGHUI | Guangzheng Ophthalmology (002524.SZ) announced that on July 20, 2023, the company repurchased the company's shares through centralized bidding for the first time through a dedicated securities account. The number of shares repurchased was 400,000 shares, accounting for 0.08% of the company's current total share capital. The maximum transaction price was 6.386 yuan/share, the minimum transaction price was 6.350 yuan/share, and the total amount paid was 2,54867 million yuan (excluding transaction fees).
Guangzheng Ophthalmology (002524.SZ): Plans to repurchase 1 million shares - 1.5 million company shares
GLONGHUI July 19丨Guangzheng Ophthalmology (002524.SZ) announced that the company plans to use its own funds to buy back some of the company's shares through centralized bidding transactions. The price of the shares to be repurchased this time is no more than 9.00 yuan/share (inclusive), the maximum number of shares to be repurchased does not exceed 1.5 million shares, accounting for about 0.2911% of the total issued share capital of the company. The lower limit of the number of shares to be repurchased is not less than 1 million shares, accounting for about 0.1940% of the company's total issued share capital. According to the current number of repurchases and the upper limit of the repurchase price, the total repurchase capital range is 9 million yuan (inclusive) - 13.5 million yuan (inclusive). The specific return
Guangzheng Ophthalmology (002524.SZ): The ophthalmology sector's performance recovered significantly in the first half of the year
GLONGHUI July 19丨Some investors asked Guangzheng Ophthalmology (002524.SZ), “What was the revenue and profit situation of the company's ophthalmology business in the second quarter?” Guangzheng Ophthalmology replied that the company's second-quarter results forecast has been released. The company's net profit for the first half of the year is expected to increase by 106.28%-109.42% year on year. The ophthalmology sector's performance in the first half of the year has recovered significantly. Specific data suggests that investors pay attention to the company's semi-annual report to be released on August 25.
Guangzheng Ophthalmology (002524.SZ): With the restoration of the external environment this year, it will further accelerate the integration of auxiliary industries and accelerate the divestment of some non-medical assets
Glonway July 19丨Some investors asked Guangzheng Ophthalmology (002524.SZ), “Does the company have plans to sell its non-ophthalmology business?” Guangzheng Ophthalmology replied that since the transformation, the company has always been firm in the strategic idea of “concentrating the ophthalmology business and accelerating the integration of auxiliary industries” and is committed to transforming into a company with ophthalmology as its single main business. Since the transformation, the company has divested more than 1 billion dollars in steel structure and energy assets to feed back the main business; this year, with the restoration of the external environment, the company will further accelerate the integration of auxiliary industries and accelerate the divestment of some non-medical assets.
Guangzheng Ophthalmology (002524.SZ): Preliminary profit of 4 million yuan in the first half of the year to 6 million yuan, reversing losses year on year
On July 13丨Guangzheng Ophthalmology (002524.SZ) announced its 2023 semi-annual results forecast. Net profit attributable to shareholders of listed companies for the reporting period was 4 million yuan to 6 million yuan, turning a year-on-year loss into a profit; net profit of 3 million yuan to 4 million yuan after deducting non-recurring profit and loss; and basic earnings of 0.01 yuan to 0.01 yuan per share. During the reporting period, the external socio-economic environment improved, and market demand for the company's ophthalmology and other businesses improved. The company gave full play to the city's brand and service advantages to accelerate business recovery. At the same time, the company achieved significant growth in revenue from ophthalmology services. At the same time, the company strengthened standardization
Analysis
Price Target
No Data
